Cargando…
State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
BACKGROUND: In 2021, the Department of Health and Human Services released guidelines allowing waiver-eligible providers seeking to treat up to 30 patients to be exempt from waiver training (WT) and the counseling and other ancillary services (CAS) attestation. This study evaluates if states and the...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206439/ https://www.ncbi.nlm.nih.gov/pubmed/37234704 http://dx.doi.org/10.1016/j.dadr.2023.100164 |
_version_ | 1785046231399006208 |
---|---|
author | Silwal, Anita Talbert, Jeffery Bohler, Robert M. Kelsch, Jordan Cook, Christopher Blevins, Derek Gallivan, Molly Hunt, Timothy Hatcher, Sarah M. Thomas, Cindy Parks Williams, Soncere Fanucchi, Laura Lofwall, Michelle R. |
author_facet | Silwal, Anita Talbert, Jeffery Bohler, Robert M. Kelsch, Jordan Cook, Christopher Blevins, Derek Gallivan, Molly Hunt, Timothy Hatcher, Sarah M. Thomas, Cindy Parks Williams, Soncere Fanucchi, Laura Lofwall, Michelle R. |
author_sort | Silwal, Anita |
collection | PubMed |
description | BACKGROUND: In 2021, the Department of Health and Human Services released guidelines allowing waiver-eligible providers seeking to treat up to 30 patients to be exempt from waiver training (WT) and the counseling and other ancillary services (CAS) attestation. This study evaluates if states and the District of Columbia had more restrictive policies preventing adoption of the 2021 federal guidelines. METHODS: First, the Westlaw database was searched for buprenorphine regulations. Second, state medical, osteopathic, physician assistant, nursing boards, and single state agencies (SSA) were surveyed to assess for the WT and CAS requirements and if they were discussing the 2021 guidelines. Results were recorded and compared by state and waiver-eligible provider types. RESULTS: The Westlaw search revealed seven states with regulations requiring the WT and ten states requiring CAS. Survey results showed ten state boards/SSAs required WT for at least one waiver-eligible practitioner type and eleven state boards/SSAs required CAS. In some states, the WT and CAS requirements only applied in special circumstances. Eleven states had discrepancies between the Westlaw and survey results among three waiver-eligible provider types. CONCLUSIONS: Despite the 2021 federal change intended to increase access to buprenorphine, several states had regulations and/or provider boards and SSAs that were not supportive. Now, the Mainstreaming Addiction Treatment (MAT) Act of 2022 eliminated the federal x-waiver requirement to prescribe buprenorphine. However, these states may continue to have barriers to treatment access despite the MAT Act. Strategies to engage states with these restrictive policies are needed to improve buprenorphine treatment capacity. |
format | Online Article Text |
id | pubmed-10206439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102064392023-05-25 State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements Silwal, Anita Talbert, Jeffery Bohler, Robert M. Kelsch, Jordan Cook, Christopher Blevins, Derek Gallivan, Molly Hunt, Timothy Hatcher, Sarah M. Thomas, Cindy Parks Williams, Soncere Fanucchi, Laura Lofwall, Michelle R. Drug Alcohol Depend Rep Full Length Report BACKGROUND: In 2021, the Department of Health and Human Services released guidelines allowing waiver-eligible providers seeking to treat up to 30 patients to be exempt from waiver training (WT) and the counseling and other ancillary services (CAS) attestation. This study evaluates if states and the District of Columbia had more restrictive policies preventing adoption of the 2021 federal guidelines. METHODS: First, the Westlaw database was searched for buprenorphine regulations. Second, state medical, osteopathic, physician assistant, nursing boards, and single state agencies (SSA) were surveyed to assess for the WT and CAS requirements and if they were discussing the 2021 guidelines. Results were recorded and compared by state and waiver-eligible provider types. RESULTS: The Westlaw search revealed seven states with regulations requiring the WT and ten states requiring CAS. Survey results showed ten state boards/SSAs required WT for at least one waiver-eligible practitioner type and eleven state boards/SSAs required CAS. In some states, the WT and CAS requirements only applied in special circumstances. Eleven states had discrepancies between the Westlaw and survey results among three waiver-eligible provider types. CONCLUSIONS: Despite the 2021 federal change intended to increase access to buprenorphine, several states had regulations and/or provider boards and SSAs that were not supportive. Now, the Mainstreaming Addiction Treatment (MAT) Act of 2022 eliminated the federal x-waiver requirement to prescribe buprenorphine. However, these states may continue to have barriers to treatment access despite the MAT Act. Strategies to engage states with these restrictive policies are needed to improve buprenorphine treatment capacity. Elsevier 2023-05-02 /pmc/articles/PMC10206439/ /pubmed/37234704 http://dx.doi.org/10.1016/j.dadr.2023.100164 Text en © 2023 The Authors. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Full Length Report Silwal, Anita Talbert, Jeffery Bohler, Robert M. Kelsch, Jordan Cook, Christopher Blevins, Derek Gallivan, Molly Hunt, Timothy Hatcher, Sarah M. Thomas, Cindy Parks Williams, Soncere Fanucchi, Laura Lofwall, Michelle R. State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
title | State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
title_full | State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
title_fullStr | State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
title_full_unstemmed | State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
title_short | State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
title_sort | state alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements |
topic | Full Length Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206439/ https://www.ncbi.nlm.nih.gov/pubmed/37234704 http://dx.doi.org/10.1016/j.dadr.2023.100164 |
work_keys_str_mv | AT silwalanita statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT talbertjeffery statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT bohlerrobertm statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT kelschjordan statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT cookchristopher statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT blevinsderek statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT gallivanmolly statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT hunttimothy statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT hatchersarahm statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT thomascindyparks statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT williamssoncere statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT fanucchilaura statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements AT lofwallmicheller statealignmentwithfederalregulationsin2022torelaxbuprenorphine30patientwaiverrequirements |